Our Pipeline

Pioneering the development of therapeutics to modulate DNA Damage Response

EPRENETAPOPT (APR-246)

Eprenetapopt, also known as APR-246, is our lead p53 reactivator product candidate. Eprenetapopt is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.

 

Eprenetapopt has received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer.

EPRENETAPOPT PIPELINE

HEMATOLOGIC
target indication
treatment line
preclinical
phase one
phase two
phase three
TP53 Mutant MDS
TP53 Mutant MDS/AML
TP53 Mutant AML
TP53 Mutant CLL/MCL
Frontline
Frontline (U.S.)
Frontline (France)
Post-transplant
Maintenance
Frontline and
Relapsed/Refractory
Relapsed/Refractory
SOLID TUMOR
target indication
treatment line
preclinical
phase one
phase two
phase three
Gastric/Bladder/NSCLC
Relapsed/Refractory

APR-548

APR-548 is our next-generation p53 reactivator that has been engineered for oral administration. APR-548 is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.

APR-548 PIPELINE

target indication
treatment line
preclinical
phase one
phase two
phase three
Hematologic
Malignancies